{"id":"atropine-ophthalmic-0-05","safety":{"commonSideEffects":[{"rate":null,"effect":"Mydriasis (pupil dilation)"},{"rate":null,"effect":"Cycloplegia (accommodation paralysis)"},{"rate":null,"effect":"Photophobia"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Ocular irritation"}]},"_chembl":{"chemblId":"CHEMBL4557433","moleculeType":"Unknown","molecularWeight":"289.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atropine is an anticholinergic agent that competitively antagonizes muscarinic receptors on the iris sphincter muscle and ciliary muscle. By blocking acetylcholine signaling, it causes mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). In the context of myopia control, atropine may work by relaxing accommodation-induced stress on the eye and potentially altering scleral remodeling.","oneSentence":"Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:53.069Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myopia control in children (Phase 3)"}]},"trialDetails":[{"nctId":"NCT07028827","phase":"PHASE3","title":"Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)","status":"RECRUITING","sponsor":"Ocus Innovation Ireland Limited","startDate":"2025-09-01","conditions":"Myopia","enrollment":234},{"nctId":"NCT06450132","phase":"PHASE4","title":"Changes in Eye Shape With Myopia Management Interventions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Myopia","enrollment":75},{"nctId":"NCT07364370","phase":"NA","title":"Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-02","conditions":"Pediatric Cataract, IOL Implantation, Myopia Progression","enrollment":50},{"nctId":"NCT05062031","phase":"NA","title":"Myopia Control in Children: Comparison of Defocus Incorporated Multiple Segments® Lenses Versus Atropine 0.05% Eyedrops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2021-10-19","conditions":"Myopia","enrollment":242},{"nctId":"NCT07176949","phase":"NA","title":"Early-Onset Myopia Intervention Project","status":"RECRUITING","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2025-06-01","conditions":"Myopia, Pre-myopia","enrollment":508},{"nctId":"NCT07164092","phase":"PHASE2, PHASE3","title":"Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-09","conditions":"Myopia","enrollment":45},{"nctId":"NCT07033442","phase":"NA","title":"Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery","status":"COMPLETED","sponsor":"Ataturk Training and Research Hospital","startDate":"2015-07-23","conditions":"Anaesthesia, Intraocular Pressure, Trendelenburg Position","enrollment":60},{"nctId":"NCT05667454","phase":"PHASE3","title":"MAD Trial: Myopia Atropine Dose","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2022-12-19","conditions":"Progressive Myopia","enrollment":550},{"nctId":"NCT05379855","phase":"NA","title":"A-eyedrops on Ocular Alignment and Binocular Vision","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-03-02","conditions":"Exotropia, Exophoria, Myopia","enrollment":339},{"nctId":"NCT05815784","phase":"PHASE2","title":"Myopia Control: a Comparison Study Between Atropine and MiSight","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2023-05-02","conditions":"Myopia","enrollment":348},{"nctId":"NCT05481489","phase":"PHASE1","title":"Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution","status":"WITHDRAWN","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2023-02-01","conditions":"Myopia","enrollment":""},{"nctId":"NCT06029530","phase":"PHASE1","title":"Delaying the Onset of Nearsightedness Until Treatment Study","status":"WITHDRAWN","sponsor":"Ohio State University","startDate":"2024-01-01","conditions":"Myopia","enrollment":""},{"nctId":"NCT06344429","phase":"NA","title":"Stellest Lenses and Low-concentration Atropine Myopia Control Among Children","status":"RECRUITING","sponsor":"Essilor-Polylite Taiwan Co., Ltd.","startDate":"2023-08-20","conditions":"Myopia","enrollment":100},{"nctId":"NCT06265454","phase":"PHASE2","title":"Low Dose Atropine Eye Drops in Myopic Egyptian Children","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-09-01","conditions":"Myopia Progression, Axial Length, Eye, Sclera Thickness","enrollment":75},{"nctId":"NCT05683535","phase":"","title":"Adverse Events Related to Low Dose Atropine","status":"COMPLETED","sponsor":"Scripps Health","startDate":"2018-06-19","conditions":"Myopia, Progressive","enrollment":148},{"nctId":"NCT05803863","phase":"PHASE4","title":"Efficacy Comparison of 2 Low-dose Atropine Eye Drops in Vietnamese Children Myopia Management","status":"UNKNOWN","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2023-04-15","conditions":"Myopia","enrollment":108},{"nctId":"NCT05597163","phase":"NA","title":"Efficacy and Safety of Low-concentration Atropine for Myopia Control in Chinese Children and Adolescents","status":"UNKNOWN","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2023-01-15","conditions":"Myopia, Progressive","enrollment":588},{"nctId":"NCT02870478","phase":"PHASE3","title":"The Effects of Low Concentration Atropine on Pupil Size and Accommodation","status":"COMPLETED","sponsor":"University of California, Berkeley","startDate":"2016-07","conditions":"Myopia","enrollment":32},{"nctId":"NCT02130167","phase":"NA","title":"Low Concentration Atropine for Myopia Progression in School Children","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2012-08","conditions":"Myopia Progression","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":288,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Atropine Ophthalmic 0.05%","genericName":"Atropine Ophthalmic 0.05%","companyName":"Erasmus Medical Center","companyId":"erasmus-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation. Used for Myopia control in children (Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}